Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

BACKGROUND: Osteoprotegerin (OPG) is a tumour and/or bone derived factor that may protect tumour cells from apoptosis. In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated...

Bibliografske podrobnosti
Main Authors:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Format:	Journal article
Jezik:	English
Izdano:	2004

Podobne knjige/članki

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
od: Eaton, C, et al.
Izdano: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
od: Holen, I, et al.
Izdano: (2002)

Role of osteoprotegerin (OPG) in cancer.
od: Holen, I, et al.
Izdano: (2006)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
od: Holen, I, et al.
Izdano: (2002)

The role of osteoprotegerin in breast and prostate cancer
od: Holen, I, et al.
Izdano: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
od: Holen, I, et al.
Izdano: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
od: Miles, L, et al.
Izdano: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
od: Gamal B Mohamed, et al.
Izdano: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
od: Holen Ingunn, et al.
Izdano: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
od: Lili Zhang, et al.
Izdano: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
od: Riham Eid, et al.
Izdano: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
od: Indra Wijaya, et al.
Izdano: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
od: Croucher, P, et al.
Izdano: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
od: Shipman, C, et al.
Izdano: (2002)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
od: Siamak Kazemi-Sufi, et al.
Izdano: (2024-09-01)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
od: Shipman, C, et al.
Izdano: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
od: Shipman, C, et al.
Izdano: (2002)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
od: Noura N. Alraouji, et al.
Izdano: (2024-08-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
od: Chan Kai-Ming, et al.
Izdano: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
od: Syed Muhammad Muneeb Akhtar, et al.
Izdano: (2024-07-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
od: Waterman, E, et al.
Izdano: (2007)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
od: Cheema, Raheem Ramzan
Izdano: (2021)

Changes of serum osteoprotegerin level in recurrent urolithiasis
od: A. V. Savilov, et al.
Izdano: (2023-10-01)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
od: Yao Jing, et al.
Izdano: (2011-03-01)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
od: Hamdy, F
Izdano: (2005)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, et al.
Izdano: (2004)

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations
od: Veselina Goranova-Marinova, et al.
Izdano: (2007-07-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
od: Yan Zhao, et al.
Izdano: (2023-07-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
od: Martin Widschwendter, et al.
Izdano: (2015-10-01)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
od: Jong-Kwang Kim, et al.
Izdano: (2021-12-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
od: F. F. Rija, et al.
Izdano: (2021-10-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
od: Yen-Liang Chen, et al.
Izdano: (2023-10-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, et al.
Izdano: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, et al.
Izdano: (2020-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, et al.
Izdano: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
od: Croucher, P, et al.
Izdano: (2001)

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis
od: Yousif Pshtiwan A., et al.
Izdano: (2023-01-01)

Serum level of osteoprotegerin in patients with Parkinson’s disease: a preliminary study
od: Marta Piaścik-Gromada, et al.
Izdano: (2024-03-01)

Effect of Lovastatin on Serum Osteoprotegerin Level in Type 2 Diabetic Nephropathy
od: N Nezami,, et al.
Izdano: (2012-07-01)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
od: Shirly Elisa Tedjasaputra, et al.
Izdano: (2018-06-01)